Crossmark

A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients – Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC)

Crossref DOI link: https://doi.org/10.1186/s12881-020-01050-w

Published Online: 2020-05-24

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Roperch, Jean-Pierre https://orcid.org/0000-0002-6745-6067
Hennion, Claude
Funding

Funding for this research was provided by:

Agence de développement pour la Normandie (19P00800)
License Information

Text and Data Mining valid from 2020-05-24

Version of Record valid from 2020-05-24
More Information

Article History

Received: 27 February 2020

Accepted: 14 May 2020

First Online: 24 May 2020

Ethics approval and consent to participate

: Free and written consent was obtained from all individuals participant of this study. Approval was obtained by the Paris Bichat-Claude Bernard hospital ethics committee (approval number: 2004/15).

: Not applicable.

: JPR and CH are founding members of OncoDiag SAS. JPR is the R&D head and CH is the CEO.

Document is current

Any future updates will be listed below